Live Date: August 5, 2021
- Time: 11:30am ET
- Program Expiration: August 5, 2022
While chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common of the acquired immune-mediated demyelinating neuropathies, it remains a challenge to differentiate it from other immune-mediated inflammatory conditions. Clinicians may also find it difficult to recognize atypical presentations of CIDP. These issues lead to delayed diagnoses, misdiagnoses, and missed opportunities for early and timely interventions.
Join experts in the management of CIDP for a comprehensive review of the symptoms and clinical features of CIDP, along with practical and successful strategies to improve diagnosis and disease assessment. The safety, efficacy, and tolerability of available treatment options will also be explored, and strategies to address barriers to optimal management and emerging concepts in disease pathophysiology that could provide new targeted options to more effectively manage CIDP will be addressed.
Because of the significant morbidity and disease burden associated with CIDP, it is critical that clinicians and their patients be on the same page in terms of diagnosis, treatment expectations, and maintenance therapy to maximize outcomes. Direct your patients with CIDP to the associated patient activity, “Becoming Empowered with CIDP: Making My Voice Heard” at NeuroCareLive.com. Patients and their caregivers will become more familiar with both current and emerging management approaches, while recognizing their role in the treatment and monitoring process.
In this insightful CME course, you can gain the latest intelligence about:
- Non-pharmacologic, pharmacologic, and alternative management options for improving pain and mobility outcomes
- Optimal dosing for CIDP treatments
- Treatments available through clinical trials
Dr. Peter Donofrio, Professor of Neurology, Vanderbilt University Medical Center
Dr. Betsy Blake, Clinical Associate Professor, College of Pharmacy, University of South Carolina